胰腺癌微环境中新标志物TNRC6C/AMPD1的预后价值及免疫浸润

IF 2.2 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Biochemistry and Biophysics Reports Pub Date : 2025-08-04 DOI:10.1016/j.bbrep.2025.102185

Yongting Lan , Wenyan Du , Yongfen Ma , Jingmei Cao

{"title":"胰腺癌微环境中新标志物TNRC6C/AMPD1的预后价值及免疫浸润","authors":"Yongting Lan , Wenyan Du , Yongfen Ma , Jingmei Cao","doi":"10.1016/j.bbrep.2025.102185","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Pancreatic cancer (PC) is a highly lethal malignancy with limited treatment options. Identifying novel prognostic biomarkers and therapeutic targets is crucial for improving patient outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive bioinformatics analysis was conducted on the Gene Expression Omnibus (GEO, GSE79668, GSE183795) and The Cancer Genome Atlas- Pancreatic Adenocarcinoma (TCGA-PAAD) datasets to identify prognostic biomarkers. The prognostic value of these biomarkers was validated through survival analysis and a Cox proportional hazards model (Cox model). A clinical phenotypic prediction model was constructed using AMPD1 and TNRC6C expression levels, with logistic regression models being built for their combination. The nomogram was constructed to visually represent the model's predictive power. Additionally, immune infiltration and single-cell analyses were performed to explore the underlying mechanisms. Functional experiments were conducted to validate the effects of these biomarkers on PC cell behavior.</div></div><div><h3>Results</h3><div>Adenosine Monophosphate Deaminase 1 (AMPD1) and Trinucleotide Repeat Containing Adaptor 6C (TNRC6C) were identified as key prognostic biomarkers for PC. High expression of these genes was associated with improved patient survival. Furthermore, AMPD1 and TNRC6C were found to be positively correlated with various immune cells, suggesting their potential role in modulating the tumor immune microenvironment. Functional experiments confirmed that these genes inhibited cancer cell proliferation, migration, invasion, and promoted apoptosis. The prognostic model based on AMPD1 and TNRC6C expression showed significant predictive accuracy, suggesting its potential clinical utility.</div></div><div><h3>Conclusion</h3><div>This study highlights the prognostic significance of AMPD1 and TNRC6C in PC. These findings provide potential new therapeutic targets for PC and warrant further investigation. The developed clinical prediction model further supports their potential utility as biomarkers for patient stratification and prognosis.</div></div>","PeriodicalId":8771,"journal":{"name":"Biochemistry and Biophysics Reports","volume":"43 ","pages":"Article 102185"},"PeriodicalIF":2.2000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Prognostic value and immune infiltration of novel markers TNRC6C/AMPD1 in pancreatic cancer microenvironment\",\"authors\":\"Yongting Lan , Wenyan Du , Yongfen Ma , Jingmei Cao\",\"doi\":\"10.1016/j.bbrep.2025.102185\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Pancreatic cancer (PC) is a highly lethal malignancy with limited treatment options. Identifying novel prognostic biomarkers and therapeutic targets is crucial for improving patient outcomes.</div></div><div><h3>Methods</h3><div>A comprehensive bioinformatics analysis was conducted on the Gene Expression Omnibus (GEO, GSE79668, GSE183795) and The Cancer Genome Atlas- Pancreatic Adenocarcinoma (TCGA-PAAD) datasets to identify prognostic biomarkers. The prognostic value of these biomarkers was validated through survival analysis and a Cox proportional hazards model (Cox model). A clinical phenotypic prediction model was constructed using AMPD1 and TNRC6C expression levels, with logistic regression models being built for their combination. The nomogram was constructed to visually represent the model's predictive power. Additionally, immune infiltration and single-cell analyses were performed to explore the underlying mechanisms. Functional experiments were conducted to validate the effects of these biomarkers on PC cell behavior.</div></div><div><h3>Results</h3><div>Adenosine Monophosphate Deaminase 1 (AMPD1) and Trinucleotide Repeat Containing Adaptor 6C (TNRC6C) were identified as key prognostic biomarkers for PC. High expression of these genes was associated with improved patient survival. Furthermore, AMPD1 and TNRC6C were found to be positively correlated with various immune cells, suggesting their potential role in modulating the tumor immune microenvironment. Functional experiments confirmed that these genes inhibited cancer cell proliferation, migration, invasion, and promoted apoptosis. The prognostic model based on AMPD1 and TNRC6C expression showed significant predictive accuracy, suggesting its potential clinical utility.</div></div><div><h3>Conclusion</h3><div>This study highlights the prognostic significance of AMPD1 and TNRC6C in PC. These findings provide potential new therapeutic targets for PC and warrant further investigation. The developed clinical prediction model further supports their potential utility as biomarkers for patient stratification and prognosis.</div></div>\",\"PeriodicalId\":8771,\"journal\":{\"name\":\"Biochemistry and Biophysics Reports\",\"volume\":\"43 \",\"pages\":\"Article 102185\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-08-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Biochemistry and Biophysics Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405580825002729\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biochemistry and Biophysics Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405580825002729","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

胰腺癌（PC）是一种高度致命的恶性肿瘤，治疗方案有限。确定新的预后生物标志物和治疗靶点对改善患者预后至关重要。方法对基因表达图谱（GEO, GSE79668, GSE183795）和癌症基因组图谱-胰腺腺癌（TCGA-PAAD）数据集进行综合生物信息学分析，鉴定预后生物标志物。通过生存分析和Cox比例风险模型（Cox模型）验证这些生物标志物的预后价值。利用AMPD1和TNRC6C的表达水平构建临床表型预测模型，并对其组合建立logistic回归模型。构建nomogram来直观地表示模型的预测能力。此外，通过免疫浸润和单细胞分析来探索潜在的机制。功能实验验证了这些生物标志物对PC细胞行为的影响。结果腺苷单磷酸脱氨酶1 （AMPD1）和三核苷酸重复序列（trucleotide Repeat Containing Adaptor 6C）被确定为PC预后的关键生物标志物。这些基因的高表达与患者生存率的提高有关。此外，AMPD1和TNRC6C与多种免疫细胞呈正相关，提示其在调节肿瘤免疫微环境中的潜在作用。功能实验证实，这些基因抑制癌细胞增殖、迁移、侵袭，促进细胞凋亡。基于AMPD1和TNRC6C表达的预后模型显示出显著的预测准确性，提示其潜在的临床应用价值。结论本研究强调了AMPD1和TNRC6C在PC中的预后意义。这些发现为PC提供了潜在的新治疗靶点，值得进一步研究。开发的临床预测模型进一步支持了它们作为患者分层和预后的生物标志物的潜在效用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Prognostic value and immune infiltration of novel markers TNRC6C/AMPD1 in pancreatic cancer microenvironment

Background

Pancreatic cancer (PC) is a highly lethal malignancy with limited treatment options. Identifying novel prognostic biomarkers and therapeutic targets is crucial for improving patient outcomes.

Methods

A comprehensive bioinformatics analysis was conducted on the Gene Expression Omnibus (GEO, GSE79668, GSE183795) and The Cancer Genome Atlas- Pancreatic Adenocarcinoma (TCGA-PAAD) datasets to identify prognostic biomarkers. The prognostic value of these biomarkers was validated through survival analysis and a Cox proportional hazards model (Cox model). A clinical phenotypic prediction model was constructed using AMPD1 and TNRC6C expression levels, with logistic regression models being built for their combination. The nomogram was constructed to visually represent the model's predictive power. Additionally, immune infiltration and single-cell analyses were performed to explore the underlying mechanisms. Functional experiments were conducted to validate the effects of these biomarkers on PC cell behavior.

Results

Adenosine Monophosphate Deaminase 1 (AMPD1) and Trinucleotide Repeat Containing Adaptor 6C (TNRC6C) were identified as key prognostic biomarkers for PC. High expression of these genes was associated with improved patient survival. Furthermore, AMPD1 and TNRC6C were found to be positively correlated with various immune cells, suggesting their potential role in modulating the tumor immune microenvironment. Functional experiments confirmed that these genes inhibited cancer cell proliferation, migration, invasion, and promoted apoptosis. The prognostic model based on AMPD1 and TNRC6C expression showed significant predictive accuracy, suggesting its potential clinical utility.

Conclusion

This study highlights the prognostic significance of AMPD1 and TNRC6C in PC. These findings provide potential new therapeutic targets for PC and warrant further investigation. The developed clinical prediction model further supports their potential utility as biomarkers for patient stratification and prognosis.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Biochemistry and Biophysics Reports Biochemistry, Genetics and Molecular Biology-Biophysics

CiteScore

4.60

自引率

0.00%

发文量

191

审稿时长

59 days

期刊介绍： Open access, online only, peer-reviewed international journal in the Life Sciences, established in 2014 Biochemistry and Biophysics Reports (BB Reports) publishes original research in all aspects of Biochemistry, Biophysics and related areas like Molecular and Cell Biology. BB Reports welcomes solid though more preliminary, descriptive and small scale results if they have the potential to stimulate and/or contribute to future research, leading to new insights or hypothesis. Primary criteria for acceptance is that the work is original, scientifically and technically sound and provides valuable knowledge to life sciences research. We strongly believe all results deserve to be published and documented for the advancement of science. BB Reports specifically appreciates receiving reports on: Negative results, Replication studies, Reanalysis of previous datasets.